Adverse graft inflammation creates resistance to the induction of allograft tolerance.
No MRI‐detectable adverse events (inflammation, tumor formation, tissue infarction) occurred despite the high number of cells infused.
The most commonly encountered adverse events were inflammation at the injection site; seven instances (10%) in six patients (40%).
In patients that received sirolimus subconjunctivally, the most frequently reported adverse event was inflammation at the injection site, manifesting as ocular discomfort; conjunctival hyperemia and chemosis [6].
The most encountered adverse event was inflammation at the injection site manifesting as conjunctival hyperemia and chemosis in patients who received sirolimus subconjunctivally.
Tissue injury is an unwanted adverse effect of inflammation.
Although this therapeutic approach is different from the approach we present in this paper (e.g. the use of a monoclonal antibody versus a soluble molecule), these results may further indicate that blocking the ICAM-1/LFA-1 interaction may cause adverse effects once inflammation is established.
Once this system fails or becomes overwhelmed, cellular debris starts to accumulate resulting in inflammation, adverse immune activation, and disease.
In patients with T1DM, cigarette smoking increased the risk of DM nephropathy, retinopathy, and neuropathy (214, 215), possibly because of adverse effects on inflammation and endothelial function.
Anyway, it remains uncertain whether these conditions are primarily a result of an impaired renal clearance of inflammatory cytokines, direct stimulation of cytokine release by uraemic milieu or simply a consequence of an adverse effect of inflammation on RRF.
